MAPK4 emerges as a novel therapeutic target for triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly. In a current study published in the journal Nature Communications, a team at Baylor College of Medicine and collaborating institutions reports that MAPK4 seems to play an important role in triple-negative breast cancer (TNBC), a devastating disease with limited therapeutic options.

source https://medicalxpress.com/news/2022-01-mapk4-emerges-therapeutic-triple-negative-breast.html